Although several states have legalized either medical or recreational marijuana, it remains illegal at the federal level. This duality in legislation means that sometimes, individuals who work with or consume state-legal cannabis face federal repercussions. However, a series of reports for spending bills released by a key House committee contain a wide range of marijuana-related provisions seeking to change this.

The directives from the House Appropriations Committee were attached to spending bills containing legislative reform provisions including previously tabled proposals that would protect state marijuana laws from federal interference as well as protect banks who work with cannabis businesses from federal retaliation. The reports direct federal agencies to reconsider firing federal workers for consuming state-legal marijuana, to promote research into cannabis and fund CBD regulations.

“The Committee encourages OPM to review its policies and guidelines regarding hiring and firing of individuals who use marijuana in states where that individual’s private use of marijuana is not prohibited under the law of the State. These policies should reflect changes to the law on marijuana usage and clearly state the impact of marijuana usage on federal employment,” states a Financial Services and General Government spending bill report.

Another report attached to the Labor, Health and Human Services, Education and Related Agencies funding bill contained a number of marijuana research provisions too. One provision called on the National Institutes of Health (“NIH”) to develop a “multipronged strategy wherein basic and clinical scientists and public health specialists work together to address the opportunities and challenges of cannabis in a comprehensive manner.”

“NIH currently supports a diverse portfolio of research on cannabinoids and the endocannabinoid system, yet this research support typically relies on narrowly tailored program announcements and grants rather than a multipronged strategy wherein basic and clinical scientists and public health specialists work together to address the opportunities and challenges of cannabis in a comprehensive manner. The Committee encourages NIDA to continue supporting a full range of research on the health effects of marijuana and its components, including research to understand how marijuana policies affect public health, to help inform marijuana policy-making in States.”

Members of the committee also noted that there is significant public interest in cannabis research. They made a recommendation to provide protections for universities that would be licensed to carry out these studies.

“Through scientific research, institutions of higher education advance our understanding and knowledge of various aspects of our world. Moreover, when in the public interest, such institutions should be able to conduct such research without fear of reprisal or loss of federal funding.”

Industry watchers believe sector players like Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) are hopeful that soon enough, the pressure mounting from House Committees will eventually bear fruit at the federal level and marijuana policies will be reformed to be more progressive.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

It is crystal clear that clinical trials are the surest way to bring new drugs into the market. While most clinical trials are costly, nine out of ten drugs in clinical development are never approved. Most of these treatments fail in clinical trials due to a lack of the desired effect, and some of these failures are attributed to poor target selection during the drug discovery process. Matching the right treatment to the right patient based on molecular biomarkers can bring more promising results in clinical trials.

Precision Medicine Requires Reliable Biomarkers

Precision medicine aims to treat patients as individuals. It also targets treating patients in stratified groups with distinct molecular profiles. Early identification and verification of biomarkers in drug development stages will ensure that the new therapies are tested on the intended patients. Besides, it will save drug development costs and reduce the attrition rate in clinical trials.

Trials that are using biomarkers in selecting patients have a higher probability of proceeding to the next levels. For instance, 10.7% of trials of cancer drugs that used biomarkers in stratifying patients got market approval. Using biomarkers in early trials can give a functional basement on how later trials can be worked to boost their chances of succeeding. Besides, despite rapid growth in precision medicine, only a few percentages of trials are stratifying patients using biomarkers.

Searching for a Perfect Biomarker

Most biological processes relate to proteins, and most drugs do target proteins and not a nucleic acid. Identifying the levels of clinically relevant proteins in samples of patients will give you more insights into the patient’s disease. It will help you in selecting the best treatment and monitor how efficiently it is working.

In the past, insufficient depth and poor reproducibility made proteomics on body fluid less sufficient. But due to new technology, clinical proteomics is becoming an area of interest.

Identification of Reliable Biomarkers from Biological Fluids is Now Possible

Innovative approaches in large scale measuring of proteins is one of the key technological advancements in proteomics. The data-independent acquisition (DIA), as it is known, gives unbiased and comprehensive results. The method is also offering quantitative proteomic profiling, which reveals reproducible and robust biomarkers even in biological fluids.

Need to Go Deep into the Plasma Proteome

Blood plasma is more natural to collect and contains a variety of proteins that indicate what’s taking place in the body of a patient. It is, therefore, a preferred fluid for biomarker discovery. Besides, it also has proteins that originate from the tissues that are nurtured by blood flow, making it a window to the body. As a result, its composition can also change regularly due to biological processes. Large scale plasma proteomics and biomarkers are now achievable according to recent studies by Nestle and Biognosys after a recent study. It was found that the levels of 271 proteins that carry fat around changed significantly after weight loss hence presenting a large number of potential biomarkers candidates. It was concluded that weight loss reduced inflammation and improved the metabolism of patients.

You can bet that biomedical companies like Genprex Inc. (NASDAQ: GNPX) are looking keenly at including the use of biomarkers during their R&D.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• House Select Committee unveils climate plan involving nuclear energy as essential in clean electric-energy production
• Global uranium prices have risen 34% since March 1 amid significant production cuts
• Energy Fuels uniquely positioned as leading U.S. uranium producer and recycler, set to capitalize on growing nuclear energy role

As the largest uranium miner in the United States, Energy Fuels (NYSE American: UUUU) (TSX: EFR) is poised to capitalize on the government’s recent push for nuclear energy. On June 30, the U.S. House Select Committee on the Climate Crisis released an action plan titled “Solving the Climate Crisis: The Congressional Action Plan for a Clean Energy Economy and a Healthy, Resilient, and Just America” that calls for net-zero greenhouse gas emissions by 2050, and net-negative emissions after that (http://nnw.fm/1ukD3). In addition, the committee’s detailed plan notes that Congress should establish a national clean-energy standard that encourages zero-emission carbon technologies — such as nuclear — to achieve net-zero emissions in the electricity sector by 2040

Recognizing that a substantial reduction in greenhouse gas emissions of the electrical energy sector is needed to minimize the effects of climate change, the report highlights nuclear power as the largest source of carbon-free energy in the country. As such, nuclear energy has an essential role in confronting the global climate challenge. Nuclear facilities are not only emissions free, but they are also the most reliable assets in the power generation mix, operating under circumstances often requiring fossil fuel and renewable energy plants to cease or curtail their operations, such as extreme weather conditions.

As the country’s leading uranium and vanadium producer, Energy Fuels is well positioned to capitalize on the growing demand for clean energy. Energy Fuels has also recycled over 6 million pounds of uranium from its alternate feed recycling program. The carbon-free electricity produced from this recycled uranium would be the equivalent of a train full of coal that stretched from Los Angeles to New York — and back again — thereby avoiding 85 million tons of CO2 emissions.  Among clean-energy options, nuclear is recognized as one of the most reliable, affordable and stable, contributing to 55% of all clean-energy production throughout the country in 2019 (http://nnw.fm/fvRMJ). In terms of carbon emissions and air pollution reduction, Energy Fuels is one of the greenest companies operating in the U.S.

As the push for clean energy gains momentum, the global market shows signs of imbalance with global demand for uranium ore concentrate estimated to exceed production by 1 billion pounds over 2019–2040. Reflecting an international surge in nuclear power activity, global uranium prices have been improving globally with a 34% increase since March 2020 amid significant production cuts due to COVID-19 (http://nnw.fm/0rKIj). The global boost for nuclear energy, combined with the declared U.S. national policy to revitalize the nuclear sector and preserve domestic infrastructure to regain U.S. global nuclear leadership, distinguishes Energy Fuels, the country’s top producer of uranium, as a clear leader in the space.

For more information, visit the company’s website at www.EnergyFuels.com.

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://nnw.fm/UUUU

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Many clinical researchers are still doing their work behind closed doors. Despite being in the middle of the pandemic, they have tried to keep their trials or tests going remotely and they would want to open again fully. It is not the researchers alone who are eager for the research sites to open. Other stakeholders, including interns, have found themselves in that dilemma.

For instance, in the U.S., the three-phase plan for reopening the country indicates that researchers may return to work soon. As your research teams are preparing to return to their work stations, the safety of patients and staff must be a top priority. Clear policies for how your staff will be conducting their research activities once they are safe to return are needed. The following safety measures can allow the safe reopening of research sites:

Recommendations from the Centers for Disease Control and Prevention

Safe distancing in the workplace is one of the safety policies that have to be in place in the working areas. It will reduce contact between people at their work stations, hence making them safe. Safe distancing will be possible by doing the following:

• Employees should be working in shifts, thus limiting the number of people within the working site.
• The number of people congregating at the conference and break rooms should also reduce.

Changing the Design of the Sites to Allow for Safe Distancing During Monitoring Hours

Your research site should have a new design to minimize close contact during monitoring hours. For instance, you may consider doing the following:

• Setting up private working areas or conference rooms for monitor(s) away from your patients and staff.
• Resolving queries through web meetings and telephones even if you are close with the monitor.
• Wearing of masks by monitors when visiting the site.

Complete Your Site Initiation Visits

It would be best if you strived to think about how the study start-up activities will continue to progress. It will enable your sponsors to come in and help you finish the following activities quickly.

• Obtain the study documents and work with your staff to complete the forms.
• Conducting all pieces of training remotely (e.g., EDC, protocol, eTMF)

Ensuring Patients are Safe During Study Visits

Proper sanitation should always be in place within your site, and washing of hands with soap and water should be a norm within site. Some of these other protocols should also be in place:

• Rearranging of patients’ waiting rooms and common areas to ensure safe distancing
• Limit face-to-face contact by conducting follow up visits remotely

Changing the Schedule of Your Business

This is an era of “new normal”; hence things will be conducted differently. It would be best if you considered whether the research activities would be taking place remotely or onsite. The following should be considered:

• Can you gain access to the institution’s Electronic Medical Records and how challenging is the process?
• Are source documents accessible, and can they be securely shared through ShareFile or Box?

By following the measures mentioned above, the reopening of research sites will be possible, and the research will also be conducted efficiently. It would be interesting to hear what companies like Predictive Oncology (NASDAQ: POAI) are doing to resume full operations after the worst of the pandemic is behind us.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

As 2018 drew to a close, Congress passed the 2018 Farm Bill, legislation that finally ended the federal prohibition of industrial hemp and all of its cannabinoids. Just a few months into 2019, there was already a booming market for cannabidiol (“CBD”), one of the over 100 chemicals produced by hemp. Initial research had found the cannabinoid effective against a variety of medical conditions and soon after it was legalized, there was a plethora of CBD products on the shelves.

As it is still new and barely regulated, the industry represents a minefield for first-time buyers who don’t know their way around. Although there are lots of good, honest firms selling CBD, there are plenty of bad players as well. So how does a customer get their money’s worth when they purchase CBD?

Buy high-quality CBD products. A sizeable percentage of the CBD products on the market are either contaminated or don’t contain nearly enough CBD. Plenty of sellers are willing to cut corners, quality-wise, and the end product isn’t as effective as it should be. High-quality contaminant free product will have enough CBD for the treatment to be effective.

Follow the instructions. CBD affects everyone in different ways. The cannabinoid interacts with a part of the nervous system called the endocannabinoid system, and how the CBD affects you depends on a variety of factors like age and gender. However, trustworthy sellers include instructions on the packaging, and each brand and product contains different dosages and might be consumed in different ways. Follow the instructions and you will steadily find out the dosage that works for you.

Keep a schedule. Cannabidiol has a long term effect when it’s used consistently. Once you’ve figured out the dosage and frequency that is most effective for you, use the CBD product consistently and preferably at the same time every day. As you do this, the CBD will steadily build up in your system and over time, smaller doses of the cannabinoid will produce stronger effects. So don’t call it quits after the first couple of days, even if it produces positive results.

Don’t forget about the other cannabinoids. THC, or delta-9 tetrahydrocannabinol, is the chemical responsible for cannabis’ infamous high. Alongside CBD, it’s one of the over 100 cannabinoids produced by the cannabis plant. When CBD is consumed in unison with other cannabinoids, it results in stronger benefits, something called the entourage effect. The chemicals work in unison and this amplifies their benefits. Full-spectrum CBD products contain CBD, other chemicals as well as terpenes.

Invest in high-quality CBD, preferably full-spectrum CBD products to take advantage of the entourage effect. Follow the instructions provided and take the cannabinoid consistently for significant positive results. If in doubt, companies like Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) are always willing to answer any questions you may have.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

• The need for efficient drug procurement and delivery has never been more in demand
• Trxade Group’s unmatched supply chain trading platform represents a unique portal to speeding up drug distribution
• Such efficiencies are key to improving margins and keeping America’s independent pharmacies alive

Not in recent memory have medical services and associated support personnel been viewed as more vital to the nation. Just as indispensable, but not as visible, are the supply chain channels through which medical supplies flow, for doctors without medicines may be so handicapped as to be useless. So too would be pharmacies where the bulk of medicines are dispensed. As a result, it is crucial that these supply chain channels operate efficiently.

One company has been working specifically toward that end. Trxade Group (NASDAQ: MEDS) has developed an integrated drug procurement and delivery platform that is improving supply chain and market efficiency, speeding up distribution of drugs while also ensuring critical transparency on prices. This is good news for independent pharmacies; direct dealing on the platform will lead to improved margins. And consumers will undoubtedly welcome the platform’s price discovery capabilities. The Trxade digital pharmaceutical exchange is set to shakeup the staid drug distribution business.

Trxade’s web-based platform has something for everyone. Patients will benefit from the lower prices its algorithms identify, while pharmacies are now more likely to avoid negative reimbursement costs, which flatten profit margins. Close to half the number of independent pharmacies operating across the nation are registered users on the Trxade platform. The company expects 2019’s signup rate—8 or 9 new pharmacies every day—to continue throughout 2020. There is good reason for those expectations. For a long time, America’s independent pharmacies haven’t been getting a good deal.

The U.S. pharmaceutical industry is a sprawling system made up of around 65,000 pharmacies. Most are branches of the large chains. A recent report provides a snapshot of the landscape (http://nnw.fm/5F8lR). CVS Pharmacy, the largest, employs 18,631 pharmacists in close to 9,105 stores. Walgreens has 17,437 pharmacists working in its 7,713 or so stores, while Rite Aid with its 4,515 stores employs 9,194 pharmacists. Walmart has less stores (4,403) than Rite Aid but employs more pharmacists (10,458). This colossal operation moves around $330 billion worth of pharmaceuticals per annum. But most of the business goes to the giant chains with their thousands of retail outlets and their ability to capture significant excess margin at the cost of the consumer, employers and government.

This leaves about one-third of the nation’s pharmacies that are run independently, that do not belong to a large corporate chain. These smaller independent pharmacies tend, on average, to be $3.5 million-per-annum enterprises owned and managed, typically, owner operated vocational pharmacists. Predictably, they struggle to stay afloat, surviving on thin margins that continuously pose an existential threat.

The presence of pharmacy benefit managers (“PBMs”) hasn’t really helped. These third party administrators of prescription drug programs were expected to reduce the purchase costs of drugs across the board and they have but the benefits have accrued to a select few. The three largest PBMs— Caremark (CVS Health) / Aetna, Express Scripts, OptumRx (UnitedHealth)—now control 76 percent of the market. And, as the Brookings Institution has pointed out in testimony to Congress, “health care markets are becoming more consolidated, causing price increases for purchasers of health services…” (http://nnw.fm/L35ua).

However, Trxade’s pharmaceutical platform gives independent pharmacies a real shot at reducing their purchasing costs, and much more. The integrated pharmaceutical services company offers not just a web-based purchasing platform for transactions between independent pharmacists and drug distributors (“B2B”), but a network of associated pharmacies with its E-Hub software, and a mail order pharmacy, as well as warehouse and drug delivery services.

Called the Trxade Exchange, the platform gives small pharmacies access to the wider pharmaceutical distribution network, allowing them to search for and view products from manufacturers, buying groups, and wholesalers on a real-time and continuous basis. Trxade is hoping that the majority of America’s 24,000 independent pharmacies, who which together have a combined annual purchasing power of over $92 billion, will eventually see how Trxade’s supportive platform that can make their businesses more profitable.

For more information, visit the company’s website at www.TrxadeGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://nnw.fm/MEDS

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

When the coronavirus pandemic reached the U.S., the FDA reacted swiftly to come up with quick solutions. In a few weeks, emergency testing was already in place, and that was an opportunity to convert some of the machines to be used as ventilators. The pandemic has paved the way for some new changes and trends, and they are going to have a significant impact on the medical industry. Here are five medical trends we could see very soon:

Approval Time is Going to be Faster

As the FDA’s emergency testing initiative is likely to expire, a backlog in approving medical devices is expected to occur due to the effects of COVID-19 as the clinical trial activities have been slowed down. Moreover, several sponsors diverted funds from clinical testing due to a significant declines in medical device sales. Several sites were also giving leave to their research personnel, leading to a sharp drop in clinical trials.

The FDA still needs to keep emergency measures in place for a period to address the backlog of issues, and this could see approval times getting shorter in the long term.

Acceptance of Remote Monitoring

Remote clinical research techniques are some of the methods that the FDA is proposing. It is considered as the preferable method since it will limit most movements during clinical studies. The FDA is also allowing some of the devices that measure body temperature and heart rate to be used remotely in the monitoring of patients, and allowing the use of these devices enables healthcare workers to access information about the patient’s vital signs. This remote monitoring has also become more comfortable due to the emergence of new enabling technology.

Use of Telemedicine for Clinical Trial Participants

Conducting meetings and evaluations is one of the protocols that were set by the FDA. Telemedicine is soon coming to the forefront in leading medical and healthcare visits. During this pandemic, virtual tools, and telemedicine are the best alternative method for site visits.

Furthermore, adding more information by sponsors will demonstrate that telemedicine is the appropriate tool for conducting clinical research.

Change to the Patients’ Recruitment Strategies

The use of social media platforms in recruiting, engaging, and retaining clinical trial participants is another factor that the FDA is encouraging at this time. It will reduce onsite visits, thus paving the way for telemedicine and home visits. The strategy will reduce the risk of virus transmission. Besides, as remote monitoring is becoming more common, so could remote recruitment strategies.

Conducting More Remote Auditing

More sponsors are resorting to using remote auditing for their clinical trial sites and internal teams. The use of Trial Master File Reviews, a remote auditing tool, is already becoming common. It is both time and cost-saving than in-person reviews. Its use may also expand as device manufactures are realizing the value and benefit of remote trial reviews. The remotely run “Practice FDA Inspection” is also useful for study teams who cannot conduct in-person exercises.

As the months roll by, these trends are likely to gather more momentum, and industry players like Genprex Inc. (NASDAQ: GNPX) may already in advanced stages of incorporating these into their operational manuals.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• Clinical studies show serotonergic psychedelics may be effective in treating anxiety, depression, addiction and more
• Interest in serotonergic psychedelics has dramatically increased within last decade
• Cybin Corp. is focused on furthering research, development of psilocybin-based medications through Serenity Life Sciences Inc.

For decades seen as a taboo substance, psychedelics today are being viewed in a powerful new light. This significant societal switch is based, at least in part, on credible clinical studies, which have shown that serotonergic psychedelics may be effective in treating anxiety, depression, addiction and even cancer (http://nnw.fm/Yx7cC). Cybin Corp., a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products as well as the functional mushroom market, appears to be a strong player in this developing new space.

“Scientific interest in serotonergic psychedelics . . . has dramatically increased within the last decade,” reported a recent article published by the American Society for Clinical Pharmacology and Therapeutics. “Clinical studies administering psychedelics with psychotherapy have shown preliminary evidence of robust efficacy in treating anxiety and depression, as well as addiction to tobacco and alcohol. Moreover, recent research has suggested that these compounds have potential efficacy against inflammatory diseases through novel mechanisms, with potential advantages over existing antiinflammatory agents. . . .

“Antiinflammatory effects may hold promise for efficacy in treatment of inflammation-related nonpsychiatric as well as potentially for psychiatric disorders,” the article, which was titled “Psychedelics as Medicines: An Emerging New Paradigm,” stated. “Serotonergic psychedelics operate through unique mechanisms that show promising effects for a variety of intractable, debilitating, and lethal disorders, and should be rigorously researched.”

This research has fueled growth in an industry based on psychedelic medication, a space where Cybin Corp. is emerging as a leader. The company is focused on furthering research and development of psilocybin-based medications through its wholly owned division, Serenity Life Sciences Inc. Psilocybin is a naturally occurring, non-habit-forming psychedelic compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms.

Cybin is committed to its mission of bringing “fungi-derived psychedelic and medicinal products into the world that may potentially drive the next discovery phase of life-changing medications to treat mental illness and other health conditions.” With that mission in mind, Cybin also has a wholly owned division, called Journey Inc. that offers branded, proprietary products targeting mental wellness, the immune system, detoxification and overall general health and wellness.

Cybin is a mushroom life-sciences company advancing psychedelic and nutraceutical-based products. Cybin is launching psilocybin-based products in jurisdictions where the substance is not banned. Simultaneously, Cybin is structuring and supporting clinical studies across North America and other regions through strategic academic and institutional partnerships.

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://nnw.fm/Cybin

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

• Pharmaceutical and health care services company Trxade Group has added new tools to its Bonum Health telemedicine platform that will help patients better inform themselves about their medical needs and their provider’s prescription recommendations
• Trxade Group operates a B2B pharmaceutical network that supports independent, neighborhood-based healthcare businesses with up-to-the-minute information on drug pricing
• The company also assists patients on a B2C basis through its subsidiaries that include Bonum Health’s telemedicine platform and Delivmeds’ pharmaceutical delivery service
• Trxade Group’s development of remote-access medical care during the past two years has proven timely in the face of restrictions on gatherings imposed during the novel coronavirus pandemic
• The company has been increasing its profile among investors with uplisting to the Nasdaq exchange and entry to the annual Russell’s Microcap Index

Growing health services provider Trxade Group (NASDAQ: MEDS) recently announced the expansion of its patient empowerment telehealth platform Bonum Health, which has added access to educational resources that can help better understand and direct their care management.

Trxade Group’s wholly owned mobile telehealth application will now link to the Merck Manual, a standard reference guide for physicians since 1899, according to the announcement. The company’s intent in further developing the Bonum Health app is to “encourage, enable, and empower patients” with information pertinent to their medical needs and provider’s drug recommendations.

Trxade Group has been undergoing significant portfolio development during recent months. The company’s mission is to help sustain independent, locally owned community pharmacies, and two years ago it boosted its own capacity to reach consumers directly when it acquired accredited Internet pharmaceutical Community Specialty Pharmacy, LLC (http://nnw.fm/8vwSD) and launched its consumer-based medication delivery app Delivmeds.com.

Trxade Group has since added its Bonum Health Hub telehealth service as a means for patients and providers to consult using mobile smart tech without a need for in-office visits. The secure, privacy-enabled technology has proven particularly timely during a year when a novel coronavirus reached pandemic-level global transmission and spurred health and government leaders to enact varied restrictions against group gatherings (http://nnw.fm/s3oUQ).

Trxade Group has this year seen its operation uplisted to the Nasdaq exchange as it has gathered funding, and last month it gained inclusion on this year’s Russell’s Microcap Index.

“This marks an exciting capital markets milestone in the growth and trajectory of our company as we continue to execute upon our growth strategy and raise awareness about the Company throughout the investment community,” Trxade Chairman and CEO Suren Ajjarapu stated in a news release at the time (http://nnw.fm/poK7m).

Trxade Group’s eBay-type B2B business model significantly lowers prescription drug costs, in part due to its emphasis on transparency. At the same time, the company’s revenues grew 94 percent during 2019 as a result of fee income for medications listed on the company’s web-based market platform (http://nnw.fm/bFr3J) and 11,400 independent pharmacies became new subscribers to the company’s platform for analyzing drug pricing on an up-to-the-minute basis.

For more information, visit the company’s website at www.TrxadeGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://nnw.fm/MEDS

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

• SRAX’s Sequire platform has grown to 75 publicly traded companies comprising 500,000+ active investors
• Sequire’s sales exceeded $2.5 million in Q2 2020 with additional $3 million expected to close in Q3
• Platform expansion set to follow definitive securities purchase agreement worth $13 million

With the importance of big data on the rise, it should come as no surprise that the finance industry is leveraging the use of data analytics to deliver increased transparency and improve communications with stakeholders on every level. SRAX (NASDAQ: SRAX), a digital marketing and consumer data management technology company, is leveraging this trend through Sequire, its innovative investor intelligence platform. Through the use of proprietary technology, Sequire unlocks big data analytics in powerful new ways that connect public companies with traders and long-term investors for communication and marketing campaigns.

Interactions between public companies, shareholders and future prospects are becoming increasingly complex, requiring innovative new strategies and creative solutions that only big data can provide. Sequire facilitates these communications through an online platform that allows public companies to monitor the activities of current investors, activate campaigns to engage existing shareholders and create marketing campaigns to attract new investment to the company.

Sequire’s success – despite the effect of COVID-19 lockdowns – has been significant so far in 2020, growing to 75 publicly-traded companies comprising 500,000+ active investors and traders with sales exceeding $2.5 million in Q2 2020 (http://nnw.fm/z6H1i). Expansion of the platform is imminent following recent news that the Company has entered into a definitive securities purchase agreement led by existing institutional investors for the purchase and sale of $13 million senior secured convertible debentures to fund a rapid expansion of the platform (http://nnw.fm/DVrg6).

“On Thursday, we announced a capital raise of $13 million, which we will use in part to fund the rapid expansion of Sequire,” said SRAX CEO and founder Christopher Miglino (http://nnw.fm/9fMKq). “Our clients have seen notable results from the platform and its related services. We’ve also seen a significant increase in the number of clients on the platform with Q2 sales hitting over $2.5 million and an additional $3 million in the pipeline, with a very high probability of closing in Q3.”

Along with Sequire, SRAX delivers a suite of specialized tools for other industries, delivering a digital competitive advantage for brands in the CPG, luxury goods and lifestyle verticals by integrating all aspects of the advertising experience into one platform. At a time when consumers are becoming increasingly aware of the value of their data, SRAX is more than several steps ahead with the company’s BIGtoken platform, comprising over 16 million users and providing them with compensation for their data while simultaneously creating reliable data sets that can be accessed by marketers for a fee.

New, innovative and creative uses of big data are increasingly being used to meet the demands of businesses looking to survive the current economic period. SRAX’s services meet this demand by giving clients the ability to target and access specific niche groups across 25,000 unique points of segmentation, providing a much-needed strategic edge to businesses of all types across almost every industry.

For more information, visit the company’s website at www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://nnw.fm/SRAX

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Federal prohibition has been a thorn in cannabis’ side for a long time. And even as tens of states move to legalize recreational and medical marijuana, it remains illegal at the federal level and this has held the industry back in many ways. For instance, state-legal cannabis cannot be considered ‘organic’, a title bestowed by the U.S. Department of Agriculture, even if the growers maintained the purported ‘organic’ standards while growing the crop. However, regulators in California, the largest legal cannabis market in the world, have unveiled proposed regulations for a program that would equal the federally bestowed ‘organic’ status.

Draft regulation for the OCal Program, a statewide certification program, was released in early May, with a public comment period open until July 7. According to the California Department of Food and Agriculture (“CDFA”), the program “will ensure that cannabis products bearing the OCal seal have been certified to consistent, uniform standards comparable to the National Organic Program.” The CDFA is required to have established the certification program for cannabis by January 1, 2021.

Growers who meet a certain set of rules, including proper use of the approved fertilizers and pesticides, will be able to apply the OCal seal to their crop, and brands looking to stand out will be able to charge their health-conscious customers a premium for OCal-certified products. California will join Washington state as the only two state-legal cannabis markets to consider an organic certification for marijuana products, and being the largest legal cannabis market in the nation, it could set a precedent for other states.

According to Kristin Nevedal, Chair and Founder of the International Cannabis Farmers Association, the state-based program will “probably instill more confidence.” Consumers are willing to spend a premium for products deemed ‘organic’, she says. “It’s recognizable, and the branding opportunities are readily apparent.” She adds that some cannabis companies have already been using the consumer appetite for organically grown cannabis and have started labeling their products ‘clean and green.’

Sarah Armstrong, policy chair for the Southern California Coalition, the largest cannabis trade association in the region, hopes the program will be cost-effective enough to be well-received by the industry. “Our hope is that the proposed program will be cost-effective enough that the cannabis industry can fully participate. Right now, testing expenses represent 10% of the cost of product production, resulting in an exceptionally pure product at no small expense. Hopefully, the Organics Program can work with cultivators to develop methods that ensure the program safeguards purity in a cost-effective manner.”

Experts say industry actors like Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) could be hoping that many other states adopt similar quality standards so that the industry is lifted as a whole.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Digital data collection has played major roles in several aspects of our lives, reduced waste and removed room for human error. For example, airlines today transfer most of the data collection function to their customers, and we are willing (and even happy) to use our mobile devices to provide all the needed data, such as our seat preferences and other personal details. Banks have done the same, and so have other service providers. However, the field of clinical research has been slow in waking up to the immense benefits of digital data collection, and we cover some of the major considerations why this should no longer be the case.

How Mobile Devices Can Be Mobilized for Clinical Research

IT consumerization has made huge inroads into daily life, and it is now common for employees to use their own laptops and other mobile devices while doing company work. This trend can be tapped in the clinical trial space by allowing study participants to use their own devices to provide any needed information, rather than employing people to make journal entries or fill out survey forms.

Data protection, device synchronization and training of all participants is crucial if the digital data collection system is to work without hiccups and potentially-costly errors for the company engaged in important clinical research.

Why Digital Data Collection is Important During Clinical Studies

Lots of clinical trials involve thousands of participants, and gathering data from them manually, and then analyzing it manually, is very costly in terms of time, personnel and other resources.

Digitization cuts through all those challenges and significantly improves the accuracy of the data collected, and that means that researchers have a higher chance of getting answers to the issues they are investigating. For example, when patients provide data on the side effects they are experiencing while on an experimental drug, regulators and drug developers have a more accurate picture of the extent of any inherent shortcomings of the drug under development.

Not Everyone is a Digital Native

If you live in a busy metropolis, it may be hard for you to imagine that there are people who don’t have access to the internet or who don’t own a smartphone. Lack of connectivity and other such issues can be a real stumbling block in efforts to digitally collect data during clinical trials. Biomedical companies and other entities engaged in clinical trials therefore need to plan carefully and design mechanisms to adapt as best they can. For example, a data collection assistant can use their device to input data provided by older persons who don’t know how to use the internet.

All in all, digital data collection is the future of clinical trials, and companies engaged in research would do well to make the transition from manual systems to largely automated ones. Sector players like Genprex Inc. (NASDAQ: GNPX) have probably fine-tuned their digital data collection systems, and they are likely to move a lot faster than their counterparts who are still doing things the traditional manual way.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• POAI improved liquidity position, streamlined capital structure with conversion of $2.1 million convertible note
• Business highlights include continued initial study to sequence ovarian tumors, validate “reach-back”
• Company closed transaction resulting in gross cash proceeds of approximately $2.2 million

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced Q1 2020 financial results and business highlights (http://ibn.fm/mFwpq) as well as receipt of cash proceeds of $2.2 million from exercise of warrants (http://ibn.fm/2n6x5).

“[POAI] improved our liquidity position and streamlined our capital structure with the conversion of a $2.1 million convertible note, previously held by me, to newly issued equity,” said POAI CEO Dr. Carl Schwartz. “This action demonstrates my confidence in the commercial viability of our work, and when combined with the additional capital we raised through an equity offering, provides us with the cash runway to fund key clinical, regulatory and operational milestones for the next several quarters. In addition, we have significantly reduced the corporate structure of our Skyline Medical business to enable it to operate independently as we consider strategic alternatives for this business.”

According to Predictive Oncology’s report, for the quarter ended March 31, 2020, company revenues increased to $295,943 compared with $255,241 for the first quarter of 2019. Gross margins remained strong at 69% for the same period, compared with 71% in the 2019 period. Other Q1 highlights included the following:

• Continued initial study to sequence ovarian tumors and validate “reach-back” process; study is on schedule to be completed Q3 2020
• Signed LOI to acquire Quantitative Medicine, a biomedical analytics and computational biology company; closed early July Q3 2020
• Signed a term sheet to acquire both BioDtech and Soluble Therapeutics and its HSC(TM) Technology; closed in Q2 2020

In addition, POAI announced the closing of a previously announced transaction resulting in gross cash proceeds of approximately $2.2 million paid to the company, prior to deducting placement agent fees and offering expenses, through the exercise of certain existing warrants by several holders to purchase an aggregate of up to 1,396,826 shares of common stock at an exercise price of $1.575 per share. The shares of common stock issued upon exercise of the existing warrants are registered for resale pursuant to a registration statement on Form S-1.

In consideration for the immediate exercise of the existing warrants for cash, the exercising holders received new unregistered warrants to purchase up to an aggregate of 1,396,826 shares of common stock at an exercise price of $1.80 per share with an exercise period of five and one-half years from the issuing date. Predictive Oncology plans to use these funds for working capital and general corporate purposes.

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through the company’s Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a road map to help individualize therapy. In addition, the company is utilizing artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow

For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• Domestic REEs increasingly in demand for use in critical modern technologies, to decrease reliance on China
• UUUU announced earlier this year it is preparing to enter REE sector
• Energy Fuels’ fully licensed and constructed White Mesa Mill could be key player in producing country’s own REE supply

Increasingly in demand, rare earth elements (“REEs”) — and where they come from — have becoming a hot topic recently (http://nnw.fm/Ei1e1). Energy Fuels (NYSE American: UUUU) (TSX: EFR), the largest uranium producer in the United States and the leading conventional producer of vanadium, is in an ideal position to leverage that rising interest as the company prepares to enter the REE sector.

“[REEs are] an awfully hot topic right now for two reasons,” reports a recent “Forbes” article. “First, they’re increasingly in demand for critical modern technologies, ranging from computer hard drives and cell phones, to new-tech applications such as batteries for EVs and clean power storage, to critical defense items such as jet engines and lasers.

“Second,” the article continues, “supply is currently dominated by China (for mining alone, for example, China has 80% market share). China has cut off supplies to countries before, and just last year threatened to do so again, in retaliation against the trade war with America.”

The article, titled “For Near-Term U.S. Decoupling From China For Rare Earth Elements, Options Are Limited — But They’re Out There,” notes that a lot of people are focused on getting the United States in a more stable situation in terms of its supply of rare earth elements. Currently, the country relies heavily on China for its supply of the valuable elements.

In part, that desire has been sparked because of a recent warning Chinese President Xi Jinping that he might ban exports of REEs to the U.S. And second, the current COVID-19 pandemic has caused many companies to take a closer look at ways to decrease their reliance on China for essential items, not just REEs, in their global supply chains.

Earlier this year, Energy Fuels announced its entry into the REE space. The company is confident that its fully licensed and constructed White Mesa Mill, which is the only uranium and vanadium mill in operation in the country today, could be a key player in re-establishing the country’s ability to produce its own supply of REEs.

UUUU chose to enter the REE industry after an intense, months-long review and testing period. The intense due diligence process included discussions with technical experts and the U.S. government, which is actively seeking a domestic source of REE minerals, which it uses for national defense. As part of this effort, President Donald J. Trump issued a series of five presidential determinations declaring domestic REE production essential to national defense.

Based in Lakewood, Colorado, Energy Fuels holds three of America’s key uranium production centers: the Nichols Ranch (“ISR”) project in Wyoming, the Alta Mesa ISR Project in Texas and the White Mesa Mill in Utah – the only conventional uranium mill operating in the United States today with a licensed capacity of more than 8 million pounds of U3O8 per year. With an asset portfolio that boasts more uranium production facilities, in-ground resources, production capacity and experienced personnel than any other producer, Energy Fuels is in a unique position to maintain its position as the leading producer of uranium in an era of viable transformation of the U.S. nuclear industry.

For more information, visit the company’s website at www.EnergyFuels.com.

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://nnw.fm/UUUU

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.